TD Cowen raised the firm’s price target on United Therapeutics (UTHR) to $400 from $350 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
Questions or Comments about the article? Write to editor@tipranks.com